CALL TO ACTION: Tell FDA to deny drugmakers’ request
Published November 14, 2024
Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW!
APC News
APC to FDA: Just say no to Lilly
Published November 8, 2024
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list.
California BOP sends proposed compounding regs to comment period
Published November 8, 2024
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period.
Checking in on the post-Chevron fallout
Published November 8, 2024
What’s happened in the world of federal regulation since the end of Chevron?
PFMs can get 2.5% credit card processing
Published November 1, 2024
A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%.
Phoenix compounders, rise!
Published November 1, 2024
The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5.
APC election results: directors and bylaws
Published November 1, 2024
See the results of APC's elections, including four new directors and several changes to our bylaws.
Bring us your expertise — join an APC standing committee
Published November 1, 2024
We’re seeking knowledgeable members for seven 2025 APC standing committees. Is that you?
You don’t have to miss our GLP-1 briefing
Published November 1, 2024
Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand.
PCAC votes against four nominated bulk drug substances
Published November 1, 2024
FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list.
Did someone mention glass houses?
Published November 1, 2024
Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants.
GLP-1s: Keep your patients informed
Published November 1, 2024
The P3 October newsletter is perfect for explaining GLP-1s to your patients.
Sterile compounders: Check your ingredients
Published November 1, 2024
FDA issued a reminder this week to only produce sterile drugs with suitable components.
Full of sound and fury, signifying nothing
Published October 25, 2024
Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.)
Video: APC on Scripps
Published October 18, 2024
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.
BREAKING: FDA allows renewed compounding of tirzepatide copies — for now
Published October 18, 2024
In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now.
FDA issues IV fluids emergency guidance
Published October 17, 2024
The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage.
The Journey to Earning the CPhT-Adv Certification from PTCB
Published October 17, 2024
Earning the Advanced Certified Pharmacy Technician Certification from the Pharmacy Technician Certification Board is a great way to boost your professional skills and career opportunities.
Technicians: Professional Development through Mentorship
Published October 17, 2024
Mentors play a crucial role in career advancement by offering guidance, encouragement, advocacy, and networking potential. Identifying the right mentor within your industry is essential.
FDA reconsiders on tirzepatide, big questions remain
Published October 15, 2024
After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list.
Reporter briefing: Patient impacts of tirzepatide shortage resolution
Published October 11, 2024
APC's media briefing shared compounders' first-hand stories with more than 30 reporters from across the country.
Be sure your marketing follows these best practices
Published October 11, 2024
APC's new guide will help you stay on the right side of laws and regs.
A fake survey from a pharma-funded organization
Published October 11, 2024
What the Partnership for Safe Medicines released "Ain't a legitimate survey."
Lots of letters
Published October 11, 2024
On the compounding front, the FDA’s inbox is getting quite a workout lately.
Slick new dosing pen for compounders
Published October 11, 2024
Love Lifesciences’ UniPen injector pen is not only a Very Big Deal, it's available at a discount for APC PFM members.
FDA says tirzepatide shortage “resolved”
Published October 2, 2024
As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound.
Get yer law and patient safety CE here
Published October 2, 2024
We've made the most popular segment of our 15-hour legal course into a standalone 3-hour, on-demand CE program.
Vet compounders: How has GFI 256 changed things?
Published October 2, 2024
Simply put, we want to know if you’ve been affected by recent FDA guidance on veterinary compounding.
